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Abstract
Background: Depression accounts for the greatest burden of disease among all mental health problems, and is
expected to become the second-highest amongst all general health problems by 2020. By the age of 75, 1 in 7
older people meet formal diagnostic criteria for depression. Efforts to ameliorate the burden of illness and personal
suffering associated with depression in older people have focussed on those with more severe depressive
syndromes. Less attention has been paid to those with mild disorders/sub-threshold depressive syndromes but
these patients also suffer impairments in their quality of life and level of functioning.
Methods/Design: The CASPER study has been designed to assemble an epidemiological cohort of people over 75
years of age (the CASPER cohort), from which we will identify those eligible to participate in a trial of collaborative
care for sub-threshold depression (the CASPER trial).
We aim to undertake a pragmatic randomised controlled multi-centre trial evaluating the effectiveness and cost-
effectiveness of collaborative care; a low intensity psychological intervention in addition to usual general
practitioner care versus usual general practitioner care alone. General practitioners from practices based in the
North of England will be asked to identify potentially eligible patients over the age of 75 years. Patients will be
sent a letter inviting them to participate in the study.
We aim to recruit approximately 540 participants for the CASPER trial. A diagnostic interview will be carried out to
ascertain trial eligibility with the major depressive episode module of the Mini International Neuropsychiatric
Interview (M.I.N.I.), eligible participants randomised to either the intervention or usual care. The primary outcome
will be measured with the Patient Health Questionnaire-9 (PHQ-9) and additional quality of life measures will be
collected. Data will be collected at baseline, 4 and 12 months for both trial and cohort participants.
Trial Registration: ISRCTN: ISRCTN02202951
Background
Problem to be addressed
Depression accounts for the greatest burden of disease
amongst all mental health problems, and is expected to
become the second-highest amongst all general health
problems by 2020 [1]. By the age of 75, 1 in 7 older
people meets formal diagnostic criteria for depression.
Projected demographic changes mean that population
strategies to tackle depression will increasingly have to
address the specific needs of older people [2]. Amongst
older people, depressive syndromes often affect people
with chronic medical illnesses [3], cognitive impairment,
social isolation or disability. Beyond personal suffering
and family disruption, depression worsens the outcomes
of many medical disorders and promotes disability [4].
Recently published National Institute for Health and
Clinical Excellence (NICE) guidelines have acknowl-
edged the symbiosis of physical health problems and
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depression [5,6]. The impairments in quality of life asso-
ciated with depression are comparable to those of major
physical illness [7].
Amongst older people, a clinical diagnosis of major
depression is the strongest predictor for impaired quality
of life (QoL) [7]. The focus has been on identifying and
treating those with more severe depressive syndromes as
set down in classificatory systems such as DSM IV [8]
major depressive disorder or ICD 10 [9] moderate/
severe depressive disorder [2]. UK policies under the
Quality and Outcomes Framework (QOF) advocate
screening for these threshold-level disorders amongst
those with chronic physical health problems such as
heart disease and diabetes [10]. Once detected, evi-
dence-supported guidelines advocate the prescription of
anti-depressant drugs and appropriate provision of psy-
chological care [5,6,11].
Less attention has been paid to those with milder disor-
ders/sub-threshold depressive syndromes or those who
give positive responses to screening questions but do not
have sufficient levels of depressive symptoms to meet diag-
nostic criteria [11]. A recent large cross-sectional study
conducted in over 20 countries [7] showed that even rela-
tively minor levels of depression are associated with a sig-
nificant decrement in all QOL domains and with a pattern
of negative attitudes toward ageing. Sub-threshold depres-
sion is also a clear risk factor for progression and the
development of more severe depressive syndromes [12].
The focus of the current study will be in a population of
screen-positive sub-threshold older adults.
The need for a trial
Primary care services have increased their focus on
screening for depression in older people. This screening
programme has enabled primary care providers to iden-
tify and treat those with severe depressive syndromes.
However, the screening programme also identifies those
with sub-threshold depression. There is currently no
clear evidence-based guidance regarding treatment for
this patient group. The rationale for screening for
depression in older people is clear, since a substantial
portion of those with depression go unrecognised and
untreated [11].
Collaborative care for older adults
The vast majority of depression in older people is mana-
ged entirely in primary care, without recourse to specia-
list mental health services [2,11]. A range of individual
treatments has been shown to be effective in the man-
agement of clinical depression in older people [11].
However, a repeated observation amongst those with
depression has been the failure to integrate these effec-
tive elements of care into routine primary care
services [13].
A new model of care has been introduced called Col-
laborative Care [14]. Collaborative care borrows much
from chronic disease management and ensures the
delivery of effective forms of treatment (such as pharma-
cotherapy and/or brief psychological therapy) and
involves augmenting the role of non-medical specialists
in primary care. The ubiquity of depression in primary
care settings and the poor integration and co-ordination
of care have led to the development and use of this
model of care. Previous studies of collaborative care
have found positive results [15-17].
In addition to the provision of collaborative care, low
intensity psychological interventions, such as Beha-
vioural Activation (BA), may benefit individuals experi-
encing depressive symptoms. BA focuses on the
behavioural deficits common amongst those with
depression and reintroduces positive reinforcement and
reduces avoidance [18]. BA is about helping patients to
‘act their way out’ of depression rather than wait until
they are ready to ‘think their way out’. The effectiveness
of this psychological approach is now well demon-
strated [19]. BA can be readily delivered either over the
phone by a trained case manager or face to face for
those who experience difficulty using or accessing
phone-based therapy [20]
Limitations of previous trials
The major limitations of previous trials are two-fold.
First, previous trials have generally included those with
above threshold-level depression and have not looked
exclusively at sub-threshold depression. Second, a key
component of collaborative care is ‘medication manage-
ment’ (encouragement of compliance and guideline-con-
cordant prescription of anti-depressants) but anti-
depressants are not indicated in those with screen-posi-
tive sub-threshold depression [5,6,11].
Identifying depressive symptoms and validating measures
of depression
Two depression tools have been in regular use in pri-
mary care: the Whooley Questions [21], a brief 2 item
depression questionnaire which has been used as a
screening tool (the Whooley questions are detailed in
Figure 1); and the Patient Health Questionnaire-9
(PHQ-9) [22] to measure depression severity once treat-
ment is initiated. Both these tools have been adopted to
fulfil QOF objectives in the UK (QOF DEP 1 and QOF
DEP 2 respectively) [23].
A number of issues have been identified in relation to
these screening tools. Firstly, neither tool has been vali-
dated in a UK elderly population. Where they have been
validated, it has been against above-threshold depression
and in non-elderly/non-UK primary care groups [24] or
non-primary care populations [21]. Secondly, little is
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known about the ability of these instruments to identify
less severe or sub-threshold levels of depression. Addi-
tionally, little is known about the significance of those
who respond with positive answers to screening ques-
tions but do not have levels of depression that meet
diagnostic criteria.
Research objectives
1. To establish the clinical effectiveness of a low
intensity collaborative care intervention for elderly
people with screen-positive sub-threshold
depression.
2. To examine the cost effectiveness of a low inten-
sity collaborative care intervention for elderly people
with screen-positive sub-threshold depression across
a range of health and social care costs.
Methods/Design
The CASPER cohort
The CASPER study has been designed to assemble an
epidemiological cohort of people over 75 years of age
(the CASPER cohort), from which we will identify those
eligible to participate in a trial of collaborative care for
sub-threshold depression (the CASPER trial; a flowchart
of the CASPER study is detailed in Figure 2). It is antici-
pated that participants in the CASPER cohort will be
given the opportunity to participate in other trials in the
future, as part of a cohort multiple RCT (cmRCT) [25].
Participants for the CASPER study will be identified via
GP practices only, no other facilities will be utilised to
identify eligible patients. All patients who have been
identified by the GP practice as eligible for an invitation
mailing will be sent an invitation pack. Patients wishing
to take part in the CASPER study will be asked to
return completed consent and background information
forms by post to the study centre. All consenting parti-
cipants will then be asked to complete a baseline ques-
tionnaire. All participants who return valid baseline data
will be included in the CASPER cohort. Inclusion in the
CASPER trial is dependent on participants meeting the
inclusion criteria and currently experiencing sub-
threshold depression. This protocol describes the meth-
ods for identifying and recruiting all participants for
both parts of the CASPER study (the epidemiological
cohort study and the trial) and, specifically, the methods
employed for the CASPER trial.
The trial has been designed as a multi-centre,
unblinded, pragmatic randomised controlled trial lasting
45 months, comprising a 6 month ‘pre-trial’ period for
refining the intervention, 12 month internal pilot trial
period, 12 month definitive trial period, 12 month fol-
low-up period and a final 3 month analysis period.
A qualitative evaluation will be carried out to examine
the acceptability of collaborative care and BA for those
over 75 and to ascertain the views of various stake-
holders in order to assess the feasibility of delivering
collaborative care and BA in the NHS. Additionally, an
economic analysis will be carried out to assess cost-
effectiveness.
Identifying sub-threshold participants
Upon receipt of a valid baseline questionnaire all parti-
cipants will be contacted by telephone to arrange a
diagnostic interview (the diagnostic interview is carried
out only once during the study); all diagnostic inter-
views will be carried out over the phone, by a trained
researcher. The major depressive episode module of
the Mini International Neuropsychiatric Interview (M.
I.N.I.) will be used to ascertain the presence or absence
of depressive symptoms and depressive disorders (sub-
threshold depression and major depressive disorder)
[26]. All participants diagnosed with sub-threshold
depression will be randomised to either the interven-
tion or control arm (see Figure 3[26-28] for the cri-
teria). Participants diagnosed as either below- or
above-threshold will not be randomised; participants
will be advised of the outcome of their diagnostic
interview and will be encouraged to remain in the
study as part of the CASPER cohort and will be
encouraged to return follow-up questionnaires. Partici-
pants diagnosed as experiencing a ‘major depressive
episode’ on the M.I.N.I. will be referred to their gen-
eral practitioner.
 
Figure 1: Whooley questions 
Question 1: ‘Over the past month, have you been bothered by feeling down, depressed or 
hopeless?’ 
 
Question 2: ‘Over the past month, have you been bothered by having little interest or pleasure 
in doing things?’ 
Figure 1 The Whooley Questions. The Whooley questions.
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The CASPER trial
Participants will be randomised into one of two groups:
(1) Collaborative Care with Behavioural Activation plus
Usual GP care intervention, or (2) Usual GP care. Parti-
cipants will be randomised by the York Trials Unit Ran-
domisation Service.
Participants randomised to the collaborative care
intervention group will be initially contacted by a case
manager to arrange their first session of collaborative
care with BA. Future sessions may be carried out either
face to face or over the phone for a period of 8-10
weeks. Participants in the control group will receive
“usual care” under their GP. We will not interfere with
usual GP care in the control arm and no treatment will
be denied to patients through participating in this trial.
Trial intervention
Intervention group: Collaborative care with behavioural
activation
Participants randomised to the intervention group will
receive low intensity collaborative care which has been
designed specifically for those aged 75 or over with sub-
threshold depression, over 8-10 weekly sessions. The
defining features of collaborative care include a case
manager working with the participant, with access to
the GP and a mental health specialist. Collaborative care
will be delivered by a case manager. If a case manager
deems depression to have deteriorated (moving from
sub-threshold to threshold) the participant will be
referred back to their GP for appropriate management;
the participant will be provided with the option of
GP/Practice Recruitment
Database screening & send 
Patient Letter of Invitation 
Baseline Mailing 
Assess for eligibility 
Ineligible – 
remain in 
cohort study 
Eligible 
Randomisation 
Collaborative 
Care 
Usual GP 
Care 
4 month follow-up 
& 
12 month follow-up 
Usual GP 
Care 
Figure 2 Flowchart of the CASPER study. Flowchart of the CASPER study.
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continuing to receive collaborative care. The additional
elements of collaborative care include: telephone sup-
port; symptom monitoring and active surveillance (facili-
tated by computerised case management systems (PC-
MIS); low intensity psycho-social management (BA).
This will be delivered according to an established proto-
col [20,29]. Participants randomised to collaborative
care will meet with a case manager for their first ses-
sion, after this initial meeting subsequent sessions will
be on a weekly basis either conducted face to face or by
telephone according to patient preference.
Control group
Participants randomised to the control group will
receive usual primary care management of sub-threshold
depression offered by their GP, in line with NICE
depression guidance as implemented by their GP and
local service provision [5,6].
Inclusion and exclusion criteria
Eligible participants will be identified from GP practice
lists. The following eligibility criteria will be used:
Inclusion:
• Aged over 75
• Screen positive to at least 1 of the Whooley [21,24]
questions and is classed as experiencing sub-thresh-
old depression during diagnostic interview based on
the M.I.N.I. (Mini-International Neuropsychiatric
Interview) [26]
Exclusion:
• Screen positive but suffering with above threshold
depression (Major Depressive Disorder) based on the
M.I.N.I. [26]
• Known alcohol dependency (as recorded on GP
records)
• Any known co-morbidity that would in the GP’s
opinion make entry to the trial inadvisable (e.g.
recent evidence of self-harm, known current
thoughts of self harm, significant cognitive
impairment)
• Other factors that would make an invitation to
participate in the trial inappropriate (e.g. recent
bereavement; terminal malignancy)
Figure 3: Diagnostic criteria for depression based on DSM-IV[26-28] 
 
Based on the 9-item depression module from the MINI participants are classified in the 
following way: 
 
• Major depressive episode: 5 or more symptoms, including one of the key symptoms 
• Sub-threshold depressive symptoms: 2-4 symptoms, may or may not include a key 
symptom 
• Non-depressed: 0-1 symptoms 
 
 
Symptoms: 
 1. Depressed mood* 
 2. Loss of interest* 
 3. Significant weight loss or gain or decrease or increase in appetite 
 4. Insomnia or hypersomnia 
 5. Psychomotor agitation or retardation 
 6. Fatigue or loss of energy 
 7. Feelings of worthlessness or excessive or inappropriate guilt 
 8. Diminished ability to think or concentrate, or indecisiveness 
 9. Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or 
suicide attempt or a specific plan 
*key symptom 
Figure 3 Diagnostic criteria for depression based on DSM-IV. Diagnostic criteria for depression based on DSM-IV.
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• Known to be experiencing psychotic symptoms (as
recorded on GP records)
Sample size calculation
To detect a minimum effect size of 0.3, with 80% power
and a two-sided 5% significance level would require 352
patients (176 in each group). Although this is an indivi-
dually-randomised trial, there may be potential clustering
at the level of each collaborative care case manager and
hence we need to inflate the sample size to account for
this. Based upon an ICC = 0.02 and a caseload size of 20,
the design effect would be 1.38 (1 + (20 - 1) × 0.02) and
we would require 486 patients (243 in each group).
Allowing for a potential loss to follow-up of 10% the final
sample size needed is 540 patients (270 in each group).
Recruitment
Recruitment will take place through GP practices in pri-
mary care. GP Practices will be recruited to the study
after a member of the study team has provided the prac-
tice with written information and visited the practice to
explain the study and what participation would entail.
Potential participants who meet the initial inclusion
criteria of being a registered patient at the participating
practice and aged over 75 years will be identified by GP
practices. The practice will be asked, at this stage, to
screen out all patients using the exclusion criteria. All
eligible patients will be sent a letter of invitation by the
practice, they will be given the opportunity to decline
participation but still provide some demographic infor-
mation and reason for declining, in order to provide
comparison information with those who are participat-
ing. All patients who consent to take part in the CAS-
PER study at this stage will be part of the CASPER
cohort.
Randomisation
Participants with sub-threshold depression who meet
the inclusion criteria and have provided written consent
will be eligible for randomisation into the trial. Rando-
misation will be carried out by the York Trials Unit
Randomisation Service using simple randomisation with
a computer based algorithm. Randomisation will be car-
ried out once all relevant data are collected and entered
into the study database. Participants will be randomised
on a 1:1 basis to either the intervention group or control
group. Participants who meet the inclusion criteria but
have below- or above-threshold depression will not be
randomised, these participants will form the cohort.
CASPER epidemiological cohort
Participants who return a completed consent form and
baseline questionnaire will be eligible for inclusion in
the CASPER cohort. This design has been termed the
“cohort multiple randomised controlled trial
(cmRCT)”, [25] with the following design features: (I)
Recruitment of a large observational cohort of patients
with the condition of interest; (II) Regular measure-
ment of outcomes for the whole cohort; (III) Capacity
for multiple randomised controlled trials over time.
Therefore, the design has the following advantages:
ongoing information as to the natural history of the
condition and to treatment as usual; and a facility for
multiple randomised controlled trials. In this case, we
are interested in following the natural history of
depressive symptoms amongst older people; comparing
health outcomes for older people with and without
depressive symptoms and potentially in the future,
using this cohort to recruit for future trials in this age
group.
Follow-up
Data collection will initially occur at five time points.
Data will be collected at invitation, baseline (pre-rando-
misation/pre-assessment), diagnostic interview for parti-
cipants entering the trial (pre-randomisation), at 4
months post-randomisation/post-assessment and 12
months post-randomisation/post-assessment for trial
and cohort participants; additionally primary care
sources will be checked for depression prescribing. With
the exception of the diagnostic interviews and depres-
sion prescribing, all participants will be sent question-
naires by post at follow-up in order to collect self-report
depression, quality of life, psychological anxiety and
medication data. The same questionnaire will be used
for trial and cohort participants.
Outcome measures
The primary outcome is depression severity and symp-
tomatology at four months as assessed by the PHQ-9 on
a continuous scale. Secondary outcomes include: depres-
sion severity and symptomatology (at 12 months), binary
description of the PHQ-9 (at 4 & 12 months), quality of
life measures (at 4 & 12 months), psychological anxiety
(at 4 & 12 months), medication (at 4 & 12 months), and
mortality (at 4 & 12 months).
Self-reported questionnaires data will be used to cap-
ture the following:
• Demographic details at invitation
• Whooley questions [21,24] at invitation and
baseline
• Questions about physical health problems at
baseline
• SF-12 [30] at baseline and follow-up
• EQ-5D [31] at baseline and follow-up
• GAD-7 [32] at baseline and follow-up
• Questions about falls at baseline and follow-up
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• PHQ-9 [33] at baseline, diagnostic interview and
follow-up
• PHQ-15 [34] at baseline and follow-up
• CD-RISC2 [35] at baseline and follow-up
Depression severity will be assessed by the PHQ-9.
Quality of life will be assessed using the SF-12 and EQ-
5D questionnaires. Psychological anxiety will be assessed
using the GAD-7. All the above measures are completed
by the participant; additionally, all participants will be
asked if they have been diagnosed with any physical
health problems. Depression medication data will be
captured by self-report and directly from GP records,
data will start to be collected from baseline onwards.
Mortality will be established by flagging all randomised
participants to the NHS Information Centre at regular
intervals.
There are likely to be some cases of loss to follow-up
due to death, this is likely to be around 8.2% per
annum (calculated from national mortality rates for
this age group). Loss to follow-up due to migration is
unlikely as this group tends to be geographically stable
and initial follow-up is only for 12 months. Where a
participant has been lost to follow-up their data will be
included in the main analysis up to where they have
been lost to follow-up. Where a participant is lost to
follow-up, efforts will be made to contact the
participant.
Data analysis
Analysis for validation of Whooley questions
The sensitivity, specificity and predictive values of the
Whooley questions will be calculated with two-by-two
contingency tables with the clinical diagnostic interview
as the gold standard. Associated 95% confidence inter-
vals will also be calculated for each estimate.
Statistical analysis
A linear regression model will be used to compare colla-
borative care with usual care on the primary outcome
adjusted for baseline depression severity (as measured
by the PHQ-9) and physical/functional limitations (as
measured by the SF-12 physical functioning scale). To
explore the potential clustering within collaborative care
case managers the primary analysis will be repeated
adjusting for the clustering using the Huber-White stan-
dard estimator (robust standard errors).
All secondary analyses will be conducted using linear
or logistic regression, depending on the outcome mea-
sure, adjusting for similar covariates to the primary ana-
lysis. In addition, for each outcome measure the number
of non-responders will be calculated for each treatment
group and response rates compared. Appropriate sensi-
tivity analyses will be used to examine the effects of
missing data on outcomes.
Withdrawal
Withdrawal can occur at any point during the study at
the request of the participant. If a participant indicates
they wish to withdraw from the study, withdrawal will
be clarified as to whether the withdrawal is from the
intervention, from follow-up or all aspects of the study.
Where withdrawal is only from the intervention then
follow-up data will continue to be collected. Data will
be retained for all participants up to the date of with-
drawal, unless they specifically request for their details
to be removed.
Economic analysis
Incremental cost-effectiveness analysis will be underta-
ken from a health and personal social services perspec-
tive following NICE guidance [36]. The economic
analysis will estimate the value for money afforded by
the collaborative care with behavioural activation and
usual GP care intervention over and above usual GP
care alone. QALYs will be estimated using the EQ-5D.
This approach enables comparisons to be made across
different health interventions and provides extra infor-
mation for decision makers. QALYs will be estimated by
measuring the area under the curve [37] which joins
baseline and follow up EQ-5D utility scores derived
from population based values.
Costs of the intervention, control and the total health
care costs during the treatment and follow up period
will be assessed. Individual take-up of depression man-
agement and control interventions will be measured and
costs will be estimated using a bottom-up approach.
Costs of the intervention, total health care costs and
changes in outcome measures in the RCT will be com-
bined to calculate the incremental cost-effectiveness
ratios. The sensitivity of the cost-effectiveness ratio to
different threshold values for a QALY will be demon-
strated using cost-acceptability curves [38].
Ethical Issues
NHS REC (National Health Service Research Ethics
Committee) approval has been obtained from Leeds
East REC (reference number 10/H1306/61) and local
approvals have been obtained through local NHS R&D
offices.
Trial Management
The chief investigator (Simon Gilbody) will be in charge
of the overall management of the trial. The York-based
trial manager (Natasha Mitchell) will be responsible for
the co-ordination of the study between sites. A trial co-
ordinator and trial secretary will carry out the day to
day activities involved in running the trial at each site.
Delivery of collaborative care will be carried out by a
dedicated & skilled case manager.
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A local trial management group will be formed at each
study centre and regular meetings will be held.
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